Drug discovery startup GTN lands £2.1m Seed from Octopus Ventures

May 4, 2018 · uktech.news

Noornew2 898x505

London-based startup GTN has raised £2.1m in Seed funding in a round led by Octopus Ventures to transform drug discovery.

Pentech and existing investor Entrepreneur First also contributed to the round, which will be used to build on GTN’s drug discovery technology.

On average, bringing a new drug to the market costs $2.9bn and takes 15 years, with a high chance of failure; plus an expected 50% drop in R&D output every nine years.

GTN, a female-led company, has developed a technology called Generative Tensorial Networks. It combines and builds upon techniques from machine learning and quantum physics to simulate, filter and discover new molecules. The company says this will help bring efficiencies to the drug development cycle, discovering much-needed medicines for patients with cancer, autoimmune and infectious diseases.

Read Complete Article

RT @unboundglobal: It's back! Save the date for #UnboundLDN: 17 & 18 July. Back at the iconic Old Truman Brewery for the sixth year with 5,…

RT @HackneyWNS: Please contact #Tell_StreetLink if you are concerned about a rough sleeper. https://t.co/pI8ezrwl1A

#TechX365: A new service designed to streamline UK company registrations has already been used more than 200,000 ti… https://t.co/0nlJj0vJcv

Workforce data has promise and a good bit of peril, says Accenture https://t.co/19G5zOVxlo by @ldignan

😊 😊 😊 Nice. Community Manager at @trussle https://t.co/Z5127xg0Sl #marketing #community